Head-To-Head Review: Lumos Pharma (NASDAQ:LUMO) vs. Ainos (NASDAQ:AIMD)

Ainos (NASDAQ:AIMD) and Lumos Pharma (NASDAQ:LUMO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk and profitability.

Analyst Recommendations

This is a summary of current ratings and target prices for Ainos and Lumos Pharma, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ainos	0	0	0	0	N/A
Lumos Pharma	0	0	3	0	3.00

Lumos Pharma has a consensus target price of $18.00, suggesting a potential upside of 542.86%. Given Lumos Pharma’s higher possible upside, analysts clearly believe Lumos Pharma is more favorable than Ainos.

Volatility and Risk

Ainos has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500. Comparatively, Lumos Pharma has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500.

Valuation and Earnings

This table compares Ainos and Lumos Pharma’s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ainos	$120,000.00	52.19	-$13.77 million	($2.55)	-0.40
Lumos Pharma	$2.05 million	11.09	-$34.03 million	($4.19)	-0.67

Ainos has higher earnings, but lower revenue than Lumos Pharma. Lumos Pharma is trading at a lower price-to-earnings ratio than Ainos, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Ainos and Lumos Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ainos	-11,205.49%	-47.96%	-40.37%
Lumos Pharma	-1,659.39%	-85.63%	-65.30%

Institutional & Insider Ownership

34.0% of Lumos Pharma shares are held by institutional investors. 4.6% of Ainos shares are held by insiders. Comparatively, 25.4% of Lumos Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Ainos beats Lumos Pharma on 7 of the 13 factors compared between the two stocks.

About Ainos

Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.

About Lumos Pharma

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company has a clinical collaboration with Massachusetts General Hospital to evaluate oral LUM-201 in nonalcoholic fatty liver disease. Lumos Pharma, Inc. is headquartered in Austin, Texas.